Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-IGFBP2-IGF1R vaccine
- Development stage
- Unknown
- Lead developer
- Aston Sci
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
HER2-IGFBP2-IGF1R vaccine (WOKVAC) is a multi-antigen, polyepitope plasmid DNA-based therapeutic cancer vaccine developed by the Cancer Vaccine Institute at the University of Washington, in collaboration with EpiThany and Aston Sci. The vaccine consists of the mammalian expression vector pUMVC3 encoding Th1-selective epitopes of three tumor-associated antigens overexpressed in breast cancer: human epidermal growth factor receptor 2 (HER2), insulin-like growth factor-binding protein 2 (IGFBP-2), and insulin-like growth factor 1 receptor (IGF-1R). Administered intradermally in combination with sargramostim (GM-CSF) as an adjuvant, the vaccine transfects local cells to express these epitopes, stimulating a robust and durable type 1 helper T-cell (Th1) immune response against tumor cells expressing these antigens. WOKVAC is being evaluated in Phase I and Phase II clinical trials for the treatment and prevention of recurrence in various breast cancer subtypes, including HER2-positive breast cancer and ductal carcinoma in situ (DCIS).
- Brand names
- WOKVAC
- Other names
- pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA VaccinepUMVC-3-IGFBP2-HER2-IGF1R Plasmid DNA VaccinepUMVC 3-IGFBP2-HER2-IGF1R Plasmid DNA VaccinepUMVC3-IGFBP2-HER2-IGF1R vaccinepUMVC-3-IGFBP2-HER2-IGF1R vaccinepUMVC 3-IGFBP2-HER2-IGF1R vaccineWOKVAC vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IGF-1R (Insulin-like growth factor 1 receptor)IGFBP2 (Insulin-like growth factor binding protein II)
Beyond the preview
Go deeper on HER2-IGFBP2-IGF1R vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-IGFBP2-IGF1R vaccine.